Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-ZIKV nanobodies
- Development stage
- Preclinical
- Lead developer
- The University of Hong Kong
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Anti-ZIKV nanobodies are single-domain antibodies (VHH) developed for the prevention and treatment of Zika virus (ZIKV) infection [5740]. Developed by researchers at the University of Hong Kong, these nanobodies were identified from a library constructed by immunizing alpacas with recombinant ZIKV proteins [5740]. They target either the ZIKV envelope (E) protein or nonstructural protein 1 (NS1), demonstrating potent neutralizing and antiviral activity in vitro and in vivo [5740]. In preclinical mouse models, treatment with these nanobodies significantly improved survival rates and reduced viral burden in brain tissues when administered as prophylaxis or therapy [5740]. Crucially, unlike conventional monoclonal antibodies, these nanobodies do not induce antibody-dependent enhancement (ADE) of infection and have been shown to downregulate interleukin-1-beta (IL-1beta) levels [5740].
- Other names
- ZIKV nanobodiesZika virus nanobodiesanti-Zika virus nanobodies
02
Targets
ZIKV E (Zika virus envelope protein)NS1 (Zika virus nonstructural protein 1)
Beyond the preview
Go deeper on anti-ZIKV nanobodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-ZIKV nanobodies.